X-Chem Announces Collaboration with Janssen and Johnson & Johnson Innovation to Advance Novel Candidates to Treat Inflammatory Diseases
WALTHAM, Mass. – January 9, 2015 – X-Chem, Inc. (“X-Chem”), a privately held biotechnology company applying its cutting-edge drug discovery platform to the generation of novel small molecule therapeutics, today announced a multi-target collaboration with Janssen Biotech, Inc. (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson. The collaboration, which is being facilitated […]
X-Chem Promotes Diala Ezzeddine to Executive Vice President and Chief Business Officer
WALTHAM, Mass. – January 9, 2015 – X-Chem, Inc., a privately held biotechnology company focused on applying its innovative drug discovery capabilities to the generation of novel small molecule therapeutics, today announced that Diala Ezzeddine, Ph.D., has been promoted to executive vice president and chief business officer, effective December 6, 2014.
X-Chem Licenses Cardiovascular Drug Discovery Program to Bayer Pharma AG
WALTHAM, Mass. – December 17, 2014 – X-Chem, Inc., a privately held biotechnology company focused on applying its innovative drug discovery capabilities to the generation of novel small molecule therapeutics, today announced it has licensed a second drug discovery program to Bayer Pharma AG pursuant to the multi-target collaboration the companies established in July 2012.